Streetbeat News

Earnings

ATRA

TLPH

In Friday's after-market session, several healthcare stocks showed notable movements. Talphera's shares surged by 15.6% following its Q4 earnings report. Other gainers included Genelux, Estrella Immunopharma, Inspire Veterinary, NRX Pharmaceuticals, and Fortrea Holdings with increases ranging from 5.02% to 10.06%. Conversely, Atara Biotherapeutics led the losers, dropping by 9.4%, followed by declines in ProKidney, Mira Pharmaceuticals, Yield10 Bioscience, GeneDx Hldgs, and Envoy Medical.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 9:31 pm

AIMD

Ainos reported a significant decrease in FY23 revenue to $122,112 from $3.52M in FY22, mainly due to reduced sales of COVID-19 Antigen Rapid Test Kits. The company's net loss slightly improved to $13.77M from $14.01M YoY. Ainos is expanding into the global pet care market through a MoU with SIDSCO and reported positive data from clinical studies of VELDONA® for oral warts in HIV patients. Additionally, Ainos is co-developing a VOC sensing platform with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co., aiming for a prototype in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:25 pm

ENTX

Entera Bio reported a narrower FY23 EPS loss of $(0.31) compared to $(0.41) YoY, with a decrease in operating expenses and net loss. The company has $11.0M in cash, expected to last through Q2 2025. R&D expenses fell to $4.5M from $5.8M, while G&A expenses dropped to $4.4M from $7.3M, contributing to a reduced net loss of $8.9M from $13.1M.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:17 pm

TGI

Triumph Group projects its Q4 2024 revenue to be in the range of $336.5M to $366.5M, compared to the estimated $354.946M by analysts.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:15 pm

TGI

Triumph Group has reaffirmed its fiscal year 2024 revenue guidance to be in the range of $1.17 billion to $1.20 billion, which is below the estimated $1.238 billion.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:15 pm

JANX

Janux Therapeutics (NASDAQ:JANX) reported Q4 earnings with EPS of $(0.25), surpassing the $(0.41) estimate, and sales of $2.46M, exceeding the $740.00K estimate. This represents a significant improvement in EPS and a substantial beat on sales forecasts, despite a slight decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:15 pm

CCL

NCLH

RCL

Carnival Corporation (NYSE:CCL) shares are trading higher after Stifel maintained a Buy rating and raised its price target from $25 to $26, citing underperformance compared to peers as a buying opportunity. Stifel anticipates Carnival could raise its full-year guidance in its upcoming report. This comes as competitors Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) and Royal Caribbean Cruises Ltd. (NYSE:RCL) reported better-than-expected earnings and raised guidance due to increased travel demand. Carnival's stock is trading around its 50-day moving average with a significant short interest. A long-term forecast suggests a challenging outlook for Carnival's stock price.

Portfolio Pulse from Erica Kollmann

March 08, 2024 | 9:01 pm

COST

Costco Wholesale Corporation (NASDAQ:COST) reported strong Q2 financial results, with analysts raising price targets and maintaining positive ratings. The company's strategic position and performance are highlighted as rare and strong, despite the stock trading near all-time highs. Analysts note improving discretionary sales, strong e-commerce growth, and potential for a membership fee increase. Costco's shares pulled back slightly after the report, attributed to high expectations and no immediate membership fee hike.

Portfolio Pulse from Chris Katje

March 08, 2024 | 8:59 pm

HURC

Hurco reported a year-over-year decrease in its Q1 financial results, leading to a decline in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 8:35 pm

HURC

Hurco reported a decrease in its Q1 2024 earnings per share (EPS) to $(0.25) from $0.20 year-over-year (YoY). Revenue also fell to $45.059M from $54.682M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 8:33 pm